CorMedix Therapeutics
Rezafungin
invasive fungal diseases
Resolved
71days ago
Phase 3 readout · Apr 27, 2026
What's at stake
Phase 3 trial results for Rezafungin in invasive fungal diseases are due Apr 27, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“EXHIBIT 99.1 CORMEDIX Therapeutics AnnounceS POSITIVE Topline Results from PHASE III respect TriaL assessing Rezzayo® for the PROPHYLAXIS of invasive fungal diseases in ALLOGENEIC Haematopoietic Stem Cell Transplantation PATIENTS”